

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 October 2024 (03.10.2024)



(10) International Publication Number
WO 2024/201240 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) A61P 35/00 (2006.01)
C07D 487/04 (2006.01) A61P 35/02 (2006.01)

(21) International Application Number:

PCT/IB2024/052766

(22) International Filing Date:

22 March 2024 (22.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/491,978 24 March 2023 (24.03.2023) US

(71) Applicant: ACERTA PHARMA B.V. [NL/NL]; Kloosterstraat 9, AB 5349 Oss (NL).

(72) Inventors: ATKINSON, Stephen; c/o AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). DE BRUIN, Gerjan; c/o Acerta Pharma B.V., Kloosterstraat 9, 5349 AB Oss (NL). IZZO, Flavia; c/o Acerta Pharma B.V., Kloosterstraat 9, 5349 AB Oss (NL). JANSEN, Chimed; c/o Acerta Pharma B.V., Kloosterstraat 9, 5349 AB Oss (NL). KINZEL, Olaf; c/o Acerta Pharma B.V., Kloosterstraat 9, 5349 AB Oss (NL). PACKER, Martin; c/o AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). VERKAIK, Saskia; c/o Acerta Pharma B.V., Kloosterstraat 9, 5349 AB Oss (NL). VOETS, Robin; c/o Acerta Pharma B.V., Kloosterstraat 9, 5349 AB Oss (NL).

(74) Agent: WALTON, Laura; ASTRAZENECA INTELLECTUAL PROPERTY, Eastbrook House, Shaftesbury Road, Cambridge Cambridgeshire CB2 8BF (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: 1-H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS ACTING AGAINST CANCER VIA AGONISM OF MENIN



(57) Abstract: Compounds having the structure of Formula (I); and pharmaceutically acceptable salts thereof, wherein R¹, R², R³, R⁴, and A are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Menin-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.

WO 2024/201240 A1